Expedite LNP Applications for Next Generation Therapeutics beyond mRNA with Optimised Formulation, Scalability & Regulatory Compliance at Forefront of Mind
2023 is set to be a landmark year for lipid-based delivery technology development and the 2nd Next-Generation Lipid-Based Nanoparticle Delivery Summit re
Yesterday, the biotechnology company Capstan Therapeutics launched with $165 million in seed and Series A funding for it to build on its foundational insights into precision in vivo
After two FDA rejections for non-alcoholic steatohepatitis (NASH) therapy obeticholic acid (OCA), Intercept Pharma has agreed to be taken over by Italian drugmaker Alfasig
Drug discovery is usually a goal-driven and iterative process, as researchers look for innovative new routes to target particular diseases and study those diseases in afflicted patients to learn ho